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San Diego, Calif
Objective: The National Kidney Foundation Dialysis Outcomes and Quality Initiative recommends autogenous access for
new dialysis procedures. The patient requiring hemodialysis with inadequate superficial arm veins represents a formidable
challenge to the surgeon. Our objective is to describe results with an alternative access procedure, the autogenous
brachial-brachial artery (ABBA) access in patients with inadequate superficial arm veins.
Methods: One surgeon created 163 new dialysis accesses in 122 patients during 40 consecutive months at a university
hospital. There was 97% patient follow-up. All patent but diminutive superficial arm veins as judged by preoperative
ultrasound were explored. Arms with inadequate veins at exploration or arms with thrombosed veins on ultrasound
received either prosthetic or ABBA procedures. Upper-arm access was often staged, involving a second “superficializa-
tion” procedure. This is a retrospective case series based on a comprehensive medical record review. Cox proportional
hazards models were used to compare access patency for individual as well as multiple factors suspected or known to
influence dialysis access outcomes. Society for Vascular Surgery reporting guidelines were used except where specifically
noted and justified otherwise.
Results: One hundred thirty-five autogenous and 28 prosthetic dialysis operations were performed. Primary patency for
all access procedures at 12, 24, and 36months was 58%, 50%, and 38%, respectively. Primary assisted patency for all access
procedures at 12, 24, and 36 months was 97%, 91%, and 85%, respectively. Secondary patency at 12, 24, and 36 months
was 99%, 97%, and 97%, respectively. Finally, functional patency at 12, 24, and 36 months was 71%, 67%, and 44.0%,
respectively. Of the 122 patients, 70 patients received either ABBA or prosthetic access. ABBA out-performed prosthetic
access in terms of primary patency (hazard ratio for prosthetic vs ABBA: 4.21 (95% confidence interval [CI]: 1.49, 11.91)
and functional patency (hazard ratio for prosthetic vs ABBA: 6.27 95% CI: 1.24-31.72) in patients referred early.
Functional patency was more likely to be compromised in elderly patients and in patients with hypercoagulable diagnoses.
Conclusions: Autogenous brachial-brachial access for dialysis out-performed prosthetic access with respect to primary and
functional patency in patients referred early without differences in overall complications. ( J Vasc Surg 2008;48:
1245-50.)End-stage renal disease (ESRD) continues to exact a
major and unrelenting cost to the United States in terms of
financial and human resources. The incidence of ESRD is
roughly 339 per million, according to the latest data avail-
able from the US Renal Data System.1 Between 1999 and
2001, vascular access maintenance procedures increased by
22% and resulted in the hospitalization of 20% of patients
with end-stage renal disease.1 The National Kidney Foun-
dation Dialysis Outcome Quality Initiative (NKF-DOQI),
in an attempt to provide some coherent and uniform guide-
lines for dialysis access creation, has championed the use of
autogenous fistulae, due to the dismal patency rates for
prosthetic grafts.2 In modern practice, the presence of an
“adequate” superficial vein such as the cephalic or basilic
vein, either in forearm or in the upper arm, should lead to
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doi:10.1016/j.jvs.2008.06.038the creation on an autogenous arteriovenous fistula. If
adequate superficial veins are not present, then typically a
prosthetic arteriovenous graft is inserted. We have previ-
ously reported on an alternative option for the creation of
an autogenous fistula, wherein an adequately sized brachial
vein is anastomosed to the brachial artery and then subse-
quently transposed to a more superficial position.3 This
report describes a more extensive experience and follow-up
with this technique in the context of all dialysis access
operations at an academic hospital in the era of DOQI.
METHODS
A retrospective review of all dialysis access operations
performed by a single surgeon from October 2003 to
February 2007 was conducted by analyzing all relevant
operative reports, imaging studies, and clinical follow-up.
The University of California, San Diego (UCSD) Institu-
tional Review Board (IRB) approval was obtained. An
intent-to-treat analysis was employed such that no patients,
other than those lost to follow-up, were excluded from the
analysis with the following exception; one access for one
patient was excluded because it became patent the same
day. It should be noted that UCSD has its own dialysis
center and as such close follow-up was facilitated. All pa-
tients were followed in the vascular surgery clinic until
access maturation and thereafter in the dialysis unit.
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sound vein mapping was a fundamental component in
determining the suitability of the superficial veins for access
surgery. The two vascular laboratories used in this study
have similar protocols for the imaging of upper extremity
veins for mapping. The cephalic and brachial veins are
imaged from the wrist to the axilla; the patency and diam-
eters are evaluated at the wrist, the forearm, the antecubi-
tus, above the elbow, and the upper arm.Until recently, the
brachial veins were not routinely imaged but because of this
experience, we have recently begun to study the brachial
veins in light of our use of the ABBA. Veins were assessed
for diameter, patency, compressibility, and wall thickening.
Access patency was defined not merely by presence of
flow but rather in terms of functional patency, which is the
ability to obtain adequate dialysis using the access. Primary,
assisted primary, and secondary patency were defined by
loss of a palpable thrill or fistula thrombosis on imaging.
Functional patency reflects the time from the first successful
cannulation until inability of the access to provide adequate
dialysis. Early referral refers to referral at least 3 months
before the need for dialysis or creatinine level4mg/dL as
adopted by the Committee on Reporting Standards for
Arterio-Venous Accesses of the Society of Vascular Sur-
gery.4 DOQI criteria and complications are reported ac-
cording to published standards and are similarly graded on
a 0-3 severity scale.4 Patients were deemed lost to follow-up
only if they received dialysis access surgery and failed post-
operative clinic visits. Surgical follow-up intervals were
individualized but always included a visit 1-week postoper-
atively and continued until the access was deemed mature.
Nephrology follow-up continued thereafter, which always
included a physical examination of dialysis accesses.
Autogenous brachial vein-brachial artery (ABBA)
technique. In our practice, vein mapping dictates which
vein in which arm will be used for the construction of the
access. When suitable superficial veins were identified on
ultrasound or at operation, the access procedures described
in Table I were created. If on ultrasound vein mapping or at
time of operation, no superficial vein of suitable quality or
diameter were present, then the brachial veins in the ante-
cubital fossa were examined. If the vein(s) were at least 2.5
mm or larger, then it was used for a brachial vein to brachial
artery anastomosis. Most of the time, the outflow vein used
for access was tested by infusing heparinized saline to
exclude any proximal obstruction and importantly, a series
of dilators were passed into the vein to corroborate size and
patency. A suitable vein had to accommodate at least a 2.5
mm dilator in order to be used for an access procedure.
The technique for creation of the staged ABBA was
previously described in detail.4 Both stages are routinely
performed under local anesthesia with intravenous sedation
or with a regional block. Briefly, a transverse incision one
finger-breadth below the antecubital crease is performed in
an effort to identify suitable brachio-cephalic/basilic veins.
In the absence of such veins, the brachial artery is exposed
under the bicipital aponeurosis along with the medial bra-
chial vein (or largest suitable brachial vein). An end-to-sideABBA anastomosis is performed with running 7-0 polypro-
pylene suture. The second stage of the operation proceeds
approximately 6 weeks later and involves mobilization of
the brachial vein with division of draining tributaries and
“superficialization” of the vein into a subcutaneous channel
in the medial upper arm. The fistula is examined closely in
clinic postoperatively and is typically ready for cannulation
after 4 to 6 weeks after the second superficialization proce-
dure.
Statistics. Differences in primary, assisted primary,
secondary, and functional patency were analyzed using Cox
proportional hazards models.5 A shared frailty component
was used to account for the fact that many patients had
multiple procedures.6 Analyses showed though that the
frailty component was not statistically significant in any of
the models, thus modeling proceeded with the standard
Cox model. For the analysis of assisted primary patency an
observation was considered censored at the time of primary
patency for patients without subsequent interventions. For
the analysis of secondary patency, an observation was con-
sidered censored at the time of primary or assisted primary
patency for patients without a secondary procedure. Pa-
tients with secondary patency but without an assisted pa-
tency were excluded from the analysis of secondary patency.
An access is said to be “functional” when it is able to deliver
a flow rate of 350 to 400 mL/min without access recircu-
lation to maintain a treatment time less than 4 hours in
accordance with SVS reporting standards.4 In models in-
cluding patients with a hypercoagulable state, this defini-
tion was limited to patients with protein C or S deficiencies,
factor V Leiden mutations, or antiphospholipid syndrome.
Factors that were associated with patency at a level of  
0.25 in univariate analyses were considered for inclusion in
multivariable models. Factors (other than procedure type)
with a P value larger than .05 were successively excluded
from multivariate models. Fractional polynomials were
used to assess the linearity assumption (on the log scale) of
continuous covariates. The proportional hazards assump-
tion was assessed using the test by Grambsch and Ther-
neau6 and score residuals7 were used to assess the influence
of individual observations on estimated parameters. For
models with at least one continuous covariate, goodness-
of-fit was also checked using the Grønnesby and Borgan
test.8 Multivariable models were only performed for pri-
mary patency and functional patency, because the number
of events were too small for multivariable models for as-
Table I. Location of access procedures (n  163)
Location Wrist
Upper
arm Forearm
Lower
extremity Total
ABBA 0 42 0 0 42
Other Autogenous 19 21 53 0 93
Prosthetic 0 16 10 2 28
Total 19 79 63 2 163
ABBA, Autogenous brachial vein-brachial artery.sisted primary and secondary patency (n 7 and 2, respec-
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complications by procedure type if all cells had an expected
value of at least five and Fisher exact tests were used if any
cell had an expected value less than five. For these compar-
isons Hochberg adjustments were used to account for
multiple comparisons. P values were not adjusted for mul-
tiple comparisons. Statistical analyses were performed using
state version 10.0 (Stata Statistical Software, Release 10,
StataCorp, College Station, Tex).
RESULTS
Patients and techniques. A total of 122 patients re-
ceived 163 new vascular accesses resulting in 135 (83%)
autogenous and 28 (17%) prosthetic shunts. Thirty-nine
percent and 49% of procedures were forearm and upper-
arm access operations, respectively; only 12% of operations
were performed using wrist veins (Table I). Four patients
were lost to follow-up prior to access maturation or evalu-
ation and excluded from all analysis. Eighty-two percent of
procedures (including superficialization procedures) were
performed under local anesthesia with intravenous seda-
tion. Patient demographics and comorbidity data are re-
ported in Table II. Mean patient age was 55.4 and 48% of
Table II. Patient characteristics (n  122)
Characteristic
Summary statistic n (%)
unless indicated otherwise
Age*
Mean 55.4
Range 13-91
Gender
Male 64 (52%)
Female 58 (48%)
Race
White 59 (48%)
Hispanic 34 (28%)
African American 15 (12%)
Other 14 (11%)
Indication
Chronic 103 (84%)
Awaiting transplant 19 (16%)
Early referral
No 47 (39%)
Yes 75 (61%)
Etiology
Hypertension 51 (42%)
Diabetes mellitus 22 (18%)
Glomerulonephritis 10 (8%)
Other 39 (32%)
Organ transplant
No 104 (85%)
Yes 18 (15%)
Transplant related (N  18) 7 (39%)
Comorbidities
Diabetes mellitus 62 (51%)
Hypertension 103 (84%)
Congestive heart failure 15 (12%)
Hyperlipidemia 42 (34%)
Atrial fibrillation 8 (7%)
Hypercoagulable state 12 (10%)patients were female. As expected, the most common eti-ologies of renal failure were hypertension and diabetes
mellitus.
Outcome analysis. Patency rates are reported in Table
III. Primary patency for all access procedures at 12, 24, and
36 months was 58%, 50%, and 38%, respectively. Primary
assisted patency for all access procedures at 12, 24, and 36
months was 97%, 91%, and 85%, respectively. Secondary
patency at 12, 24, and 36 months was 99%, 97%, and 97%,
respectively. Finally, functional patency at 12, 24, and 36
months was 71%, 67%, and 44.0%, respectively. Twenty-
one (13%) patients required a single new access, 7 (4%)
required two additional accesses, and 2 (1%) patients re-
quired three or more new accesses.
Kaplan-Meier curves applied to primary and functional
patency rates are presented in the Fig. Inclusion of standard
errors of Kaplan-Meier estimates is recommended by SVS
guidelines.4 (Appendix, online only) These are not pre-
sented in the Fig because of the necessity of presenting
multiple estimates due to the significant interaction be-
tween procedure type and early referral. Evident from the
patency analysis is the superiority of ABBA over prosthetic
access for patients who were referred early. Cox hazard
ratios indicate that primary patency was significantly pro-
longed (hazard ratio for prosthetic vs ABBA: 4.21, 95%
confidence interval [CI]: 1.49, 11.91) in patients with
ABBA procedures compared to prosthetic procedure
within the group of patients who were referred early (Table
IV). There was no difference between ABBA and prosthetic
access among patients not referred early (hazard ratio for
prosthetic vs ABBA: 1.04, 95% CI: 0.39, 2.79). There were
no statistically significant differences in primary patency
rates between ABBA and other autogenous access. Univar-
iate analyses of assisted patency showed no significant dif-
ferences between procedure type for primary, assisted pri-
mary and functional patency, but assisted primary patency
was significantly longer if referred early and significantly
shorter if atrial fibrillation was present. As for functional
patency, the relative risk of access failure was larger for
patients with a prosthetic procedure compared with pa-
tients with ABBA (hazard ratio for prosthetic vs ABBA:
6.27, 95% CI: 1.24-31.72) within the group of patients
referred early (Table IV). Although not statistically signifi-
cant, functional patency appeared to be shorter for ABBA
compared with prosthetic procedures if referred early. Fi-
nally, in the model for functional patency, advanced age
and hypercoagulable conditions resulted in significantly
increased risk, a 33% increase in risk for each additional 10
years in age (95% CI: 1.08, 1.63) and a 3.99-fold increase
for the presence of a hypercoagulable diagnosis (95% CI:
1.66, 9.02). There were no statistically significant differ-
ences in functional patency rates between ABBA and other
autogenous access.
The 30-day mortality was 0%. There was a total of 83
complications reported for 75 procedures and for 88 pro-
cedures no complications were reported. Venous hyperten-
sion occurred in one ABBA access, none of the patients
receiving prosthetic access, and in four other autogenous
accesses. When comparing complications by procedure
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occurred, there were no statistically significant differences
between the procedures. All patients with this complication
had a history of either in-dwelling pacemaker leads or
multiple previous central venous catheters resulting in se-
vere central venous stenosis. There were three patients with
access-related hand ischemia which resolved without the
need for remedial operation (Table V). Finally, three ABBA
procedures showed inadequate maturation (7.5%) and re-
quired conversion to a prosthetic graft.
DISCUSSION
The era of the NKF-DOQI began in late 1990s
marked by an increased awareness of dialysis access under-
performance and prosthetic graft over-utilization. Current
DOQI recommendations are for a 65% prevalent functional
arteriovenous fistula (AVF) rate.1We have herein described
a relatively large case series of patients with medium-term
follow-up who received the autogenous brachial-brachial
fistula due to a lack of usable superficial arm veins in the era of
DOQI. Follow-up was 97%. All operations were supervised
by a single attending surgeon, which limits the variability of
many large case series, but also limits generalizability. In-
spection of the Fig reveals that the ABBA patency curve is
similar to the patency rate of the other autogenous fistulae
when early referral was possible. Reluctance to perform the
ABBA procedure might result from the possibility that
arterializing the brachial vein would result in access-related
Table III. Number at risk, percent patent, and standard e
months
0 6
Primary patency
ABBA 42 28 18
Other autogenous 93 62 41
Prosthetic 28 10 5
Percent patent 100 68 58
Standard error 0.037 0
Assisted primary patency
ABBA 42 28 20
Other autogenous 90 62 46
Prosthetic 26 10 5
Percent patent 100 99 97
Standard error 0.007 0
Secondary patency
ABBA 42 28 20
Other autogenous 93 64 47
Prosthetic 28 12 6
Percent patent 100 99 99
Standard error 0.007 0
Functional patency
ABBA 38 23 18
Other autogenous 80 55 39
Prosthetic 25 8 3
Percent patent 100 73 71
Standard error 0.038 0
ABBA, Autogenous brachial artery-brachial vein fistula.hand ischemia and venous hypertension. Martin et al re-ported in 2000 on 15 patients with brachial arteriovenous
fistula with close imaging follow-up.9 They found that
brachial artery flows increased to 700 mls/min postopera-
tively and fistula flows greater than 400mls/min at 2 weeks
predicted success. Finally, Martin et al reported reductions
in exercise induced digital arterial pressures and hand clau-
dication was present in 26% of patients. While we specifi-
cally did not perform exercise digital arterial pressures,
hand claudication has not been an issue in our experience.
Patients with impaired functional patency were more
likely to be older, and this is especially worth noting as
others have published that the success rate of dialysis access
surgery may be inferior in the elderly patient. Indeed, Rao
et al reported a series of 56 patients who received basilic
vein transpositions and found that age greater than 60 was
associated with poorer maturation and patency.10 Dimin-
ished functional patency was also observed in patients with
the diagnosis of a hypercoagulable condition. A number of
other authors have reported on the rate of early and recur-
rent thromboses that plagues these patients.11,12
The first modern description of the transposed brachial
vein fistula was by Bazan et al in 2004.13 They described
two patients with inadequate superficial arm veins who
received a similar transposition of the brachial vein, toler-
ated the reconstruction without access-related hand ische-
mia or other complications, and successfully received he-
modialysis during their 1 year of follow-up. Recently,
Dorobantu et al reported their experience with 33 attempts
(Greenwood formula) at 0, 6, 12, 18, 24, 30, and 36
Months
18 24 30 36
10 5 4 2
26 16 9 2
0 0 0 0
52 50 38 38
0.45 0.047 0.065 0.065
13 8 7 5
31 19 12 4
1 1 0 0
97 91 91 85
0.019 0.044 0.044 0.075
13 8 7 5
31 19 12 4
2 1 0 0
97 97 97 97
0.019 0.019 0.019 0.019
10 8 4 1
22 16 8 4
2 1 0 0
70 67 55 44
0.041 0.048 0.075 0.115rror
12
.041
.019
.007
.039at the autogenous brachial-brachial fistula.14 A total of
rimar
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follow-up was 14 months with a patency of 85.2% in line
with our results. In contrast to our results, they noted arm
edema in at least one-third of patients.
In a recent series reported by Woo et al, 190 patients
underwent transposed autogenous upper-arm fistulae con-
current to 166 prosthetic procedures.15 Illustrating the
importance of “fistula first,” the 5-year secondary patency
for the transposed autogenous and prosthetic groups
were 57% and 17%, respectively. In the absence of usable
Fig. Kaplan-Meier analysis of p
Table IV. Hazard ratios and 95% confidence intervals for
type of prodedure by referral status
Early referral
Other autogenous
vs ABBA
Prosthetic vs
ABBA
Primary patency
No 1.53 (0.71, 3.30) 1.04 (0.39, 2.79)
Yes 1.08 (0.45, 2.55) 4.21 (1.49, 11.91)
Functional patency*
No 1.59 (0.63, 4.03) 0.65 (0.19, 2.16)
Yes 2.86 (0.62, 13.22) 6.27 (1.24, 31.72)
ABBA, Autogenous brachial vein-brachial artery.
*Adjusted for age and hypercoagulable state.cephalic/basilic veins, we proceed with the autogenousbrachial vein-brachial artery access which has allowed our
center to achieve a prevalent functional fistula rate at 24
months of 67%, exceeding the recommendations of 65% set
forth in DOQI guidelines.
Because the methodology of this report involved nei-
y and functional access patency.
Table V. Complications by fistula type (n  163)
Type ABBA
Other
autogenous Prosthetic Total
Bleeding 1 1 0 2
Infection 0 1 1 2
Non-infectious fluid
collections 0 1 2 3
Anastomotic
complications 4 8 1 13
Mid-AV access/runoff
complications 1 1 0 2
Access thrombosis 4 16 9 29
AV access malfunction 8 12 4 24
Access-related hand
ischemia 1 0 1 2
Venous hypertension 1 4 0 5
Miscellaneous 0 1 0 1
ABBA, Autogenous brachial vein-brachial artery; AV, arterio-venous fistula.ther a prospective design nor blinded randomization, cau-
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the data. For instance, internal bias does exist when patients
undergo multiple operations and thus induce correlated
observations. Our analyses showed that such correlation
appears not to be statistically significant, but the potential
for bias remains. It is also possible that surgeon bias in the
analysis of complications and other less definable factors
contribute to the choice of operations performed. Finally, it
should be emphasized that our statistical analysis could
only distinguish a benefit of ABBA in patients referred
greater than 3 months before the need for dialysis. It is
difficult to determine the reason for a nondifferential
effect for primary patency if early referral was not
achieved (Table IV).
A tailored approach for dialysis access surgery is critical;
we approach the majority of patients with inadequate su-
perficial arm veins in a similar fashion. When upon explo-
ration of the antecubital fossa, a superficial vein fistula
appears not feasible, the biceps aponeurosis is opened and
the brachial veins inspected. At this point, if the vein is of
adequate diameter, an autogenous fistula is created. We
prefer to then allow for maturation of the vein for 6 weeks
or so before the superficialization is performed. If at that
exploration, the maturation is unsatisfactory, then a pros-
thetic arteriovenous graft is placed. An important point is
that the brachial vein can be interrogated preoperatively on
duplex, but exploration almost always results in a useable
brachial vein for ABBA.
CONCLUSIONS
With ever improving results with renal replacement
therapy to sustain the lives of both the young and the
elderly afflicted with renal disease, hemodialysis access must
be durable. It is appears that autogenous accesses out-
perform prosthetic grafts in patients referred early. We
report here that, in the absence of superficial arm veins, the
autogenous brachial-brachial access performs as well as
other autogenous accesses and is superior to prosthetic
access if patients are referred early. Given that currently, the
absence of superficial veins for autogenous access, includ-
ing a transposable basilic vein, leads to the insertion of a
prosthetic graft, we would suggest that incorporation of the
ABBA into practice would provide yet one more potential
option for autogenous access, which, in this study, has
superior patency rates compared with prosthetic access, and
equivalent patency rates to conventional autogenous access
procedures in this patient cohort. Further research is nec-
essary to determine whether these results can be validated
in settings wheremultiple surgeons perform the procedures
and to investigate further differences between the proce-
dures in patients referred later than desired.AUTHOR CONTRIBUTIONS
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id identification number (anonymized)
ttpp time to primary patency
censorpp censoring indicator (1event)
ttapp time to assisted primary patency
censorapp censoring indicator (1event)
ttsp time to secondary patency
censorsp censoring indicator (1event)
ttfp time to functional patency
censorfp censoring indicator (1event)
type3cat Type of procedure
doqi Early referral (1yes, 0no)
age Age at procedure start
hs hypercoagulable state
id,ttpp,censorpp,ttapp,censorapp,ttsp,censorsp,ttfp,censorfp,
type3cat,doqi,age,hs
1,24,0,24,0,24,0,40,0,“OthAuto”,1,42,0
2,36,0,36,0,36,0,34,0,“ABBA”,1,66,0
3,9,0,9,0,9,0,7,0,“OthAuto”,0,59,0
4,14,0,14,0,14,0,12,0,“OthAuto”,1,54,0
5,.1,1,.1,0,.1,0,.1,1,“OthAuto”,0,34,1
6,5,1,5,0,5,0,0,1,“OthAuto”,1,49,1
7,28,0,28,0,28,0,25,0,“OthAuto”,1,36,0
8,40,0,40,0,40,0,39,0,“OthAuto”,1,44,0
8,3,1,3,0,3,0,0,1,“OthAuto”,1,44,0
9,4,1,4,0,4,0,1,1,“Prosth”,0,91,0
10,7,0,7,0,7,0,5,0,“Prosth”,1,73,0
11,29,0,29,0,29,0,26,0,“OthAuto”,1,68,0
12,.1,1,.1,0,.1,0,.1,1,“OthAuto”,0,55,0
12,9,0,9,0,9,0,7,0,“OthAuto”,0,55,0
13,12,0,12,0,12,0,11,0,“Prosth”,1,89,0
13,2,1,2,0,2,0,1,1,“Prosth”,1,89,0
14,16,1,20,0,20,0,18,0,“OthAuto”,1,54,0
14,8,1,,,16,1,7,1,“OthAuto”,1,52,0
15,.1,1,.1,0,.1,0,.1,1,“OthAuto”,0,83,0
15,21,0,21,0,21,0,19,0,“ABBA”,0,83,0
15,9,0,9,0,9,0,7,0,“Prosth”,0,85,0
15,28,1,28,0,28,0,26,1,“ABBA”,0,83,0
16,5,0,5,0,5,0,4,0,“ABBA”,1,65,1
16,.1,1,.1,0,.1,0,0,1,“ABBA”,1,65,1
16,2,1,2,0,2,0,1,1,“Prosth”,1,65,1
17,7,1,9,0,9,0,7,0,“OthAuto”,0,43,0
18,15,0,15,0,15,0,13,0,“OthAuto”,1,35,1
19,19,0,19,0,19,0,16,0,“OthAuto”,1,80,0
20,.1,1,.1,0,.1,0,.1,1,“ABBA”,0,56,0
20,4,0,4,0,4,0,2,0,“ABBA”,0,56,0
21,18,0,18,0,18,0,16,0,“OthAuto”,1,60,0
22,6,1,8,1,8,0,6,1,“OthAuto”,0,70,0
23,.1,1,,,1,1,.1,1,“OthAuto”,0,66,0
23,.1,1,.1,0,.1,0,5,1,“OthAuto”,0,66,0
24,9,0,9,0,9,0,8,0,“Prosth”,0,55,1
24,.1,1,.1,0,.1,0,.1,1,“ABBA”,0,55,1
25,10,1,,,8,0,7,0,“OthAuto”,1,43,1
25,.1,1,.1,0,.1,0,.1,1,“Prosth”,1,42,1
25,.1,1,.1,0,.1,0,.1,1,“ABBA”,1,42,1
25,.1,1,.1,0,.1,0,.1,1,“OthAuto”,1,42,1
26,11,0,11,0,11,0,7,0,“ABBA”,1,60,1
27,3,1,3,0,3,0,.1,1,“OthAuto”,0,34,0
28,14,1,40,0,40,0,26,0,“ABBA”,1,71,0
29,15,1,16,0,16,0,9,0,“OthAuto”,1,34,0
30,5,0,5,0,5,0,3,0,“ABBA”,0,73,0
31,37,0,37,0,37,0,32,0,“OthAuto”,1,36,0
32,.1,1,.1,0,.1,0,.1,1,“OthAuto”,1,60,1
33,2,1,2,0,2,0,1,1,“Prosth”,0,65,0
34,21,0,21,0,21,0,19,0,“OthAuto”,1,74,0
35,18,0,18,0,18,0,16,0,“ABBA”,0,83,0
36,20,1,40,0,40,0,41,0,“ABBA”,0,25,0
37,4,0,4,0,4,0,2,0,“OthAuto”,0,32,0Appendix, online only. Continued.
38,10,0,10,0,10,0,8,0,“OthAuto”,1,40,0
38,7,1,7,0,7,0,0,1,“OthAuto”,1,40,0
39,18,0,18,0,18,0,12,0,“OthAuto”,1,52,0
40,.1,1,.1,0,.1,0,.1,1,“OthAuto”,0,52,0
40,10,0,10,0,10,0,8,0,“OthAuto”,0,52,0
41,7,0,7,0,7,0,5,0,“OthAuto”,1,75,0
42,30,1,30,0,30,0,28,0,“OthAuto”,0,51,0
43,19,0,19,0,19,0,,,“OthAuto”,1,72,0
44,20,0,20,0,20,0,19,0,“ABBA”,1,54,0
45,30,0,30,0,30,0,28,0,“OthAuto”,1,63,0
46,15,0,15,0,15,0,14,0,“Prosth”,0,41,0
47,.5,1,1,1,1,0,0,1,“ABBA”,1,48,0
47,35,0,35,0,35,0,33,0,“OthAuto”,1,48,0
48,12,0,12,0,12,0,10,0,“OthAuto”,1,40,0
49,8,1,8,0,8,0,0,1,“ABBA”,0,76,0
49,2,1,12,1,12,0,8,1,“OthAuto”,0,75,0
49,3,1,3,0,3,0,.1,1,“Prosth”,0,76,0
50,2,1,2,0,2,0,0,1,“OthAuto”,1,78,0
51,.5,1,43,0,43,0,39,0,“OthAuto”,1,53,0
52,16,0,16,0,16,0,13,0,“OthAuto”,1,13,0
53,6,1,29,0,29,0,23,0,“OthAuto”,0,64,0
54,8,0,8,0,8,0,6,0,“OthAuto”,1,61,0
55,5,0,5,0,5,0,3,0,“OthAuto”,0,28,1
55,3,1,3,0,3,0,0,1,“OthAuto”,0,26,1
55,26,1,32,1,32,0,30,1,“OthAuto”,0,26,1
56,21,0,21,0,21,0,13,0,“ABBA”,0,61,0
57,24,0,24,0,24,0,22,0,“OthAuto”,1,74,0
58,4,0,4,0,4,0,,,“ABBA”,1,53,0
59,6,0,6,0,6,0,3,0,“ABBA”,1,54,0
60,19,0,19,0,19,0,16,0,“OthAuto”,0,73,0
61,10,0,10,0,10,0,7,0,“OthAuto”,0,47,0
62,3,1,3,0,3,0,3,1,“Prosth”,1,48,0
62,31,0,31,0,31,0,29,0,“OthAuto”,1,54,0
63,.1,1,.1,0,.1,0,.1,1,“OthAuto”,1,61,0
64,18,0,18,0,18,0,16,0,“OthAuto”,1,70,0
65,6,1,12,0,12,0,8,0,“OthAuto”,0,46,0
66,2,1,2,0,2,0,2,1,“OthAuto”,0,49,0
66,12,1,38,1,38,0,36,1,“OthAuto”,0,49,0
67,11,0,11,0,11,0,,,“OthAuto”,0,64,0
68,3,1,3,0,3,0,0,1,“OthAuto”,1,39,0
69,4,1,4,0,4,0,4,1,“Prosth”,1,76,0
70,17,0,17,0,17,0,16,0,“ABBA”,1,24,0
71,33,0,33,0,33,0,24,0,“ABBA”,1,76,0
72,4,1,4,0,4,0,.1,1,“ABBA”,0,87,0
72,9,0,9,0,9,0,8,0,“Prosth”,0,87,0
73,7,0,7,0,7,0,3,0,“ABBA”,0,57,0
74,20,0,20,0,20,0,16,0,“OthAuto”,1,44,0
75,7,1,13,0,13,0,11,0,“ABBA”,0,48,0
76,8,1,8,0,8,0,6,1,“OthAuto”,1,41,0
76,5,1,5,0,5,0,3,1,“OthAuto”,1,41,0
76,1,0,1,0,1,0,5,0,“Prosth”,1,42,0
77,29,0,29,0,29,0,28,0,“OthAuto”,1,36,0
78,6,0,6,0,6,0,3,0,“Prosth”,1,73,0
79,17,0,17,0,17,0,15,0,“OthAuto”,0,78,0
80,13,1,40,0,40,0,26,0,“ABBA”,1,54,0
81,7,1,8,0,8,0,5,0,“ABBA”,1,70,0
81,.1,1,.1,0,.1,0,.1,1,“OthAuto”,1,70,0
81,7,1,7,0,7,0,.1,1,“OthAuto”,1,70,0
82,5,0,5,0,5,0,4,0,“Prosth”,1,37,0
82,1,1,1,0,1,0,0,1,“Prosth”,1,37,0
83,39,0,39,0,39,0,35,0,“ABBA”,1,39,0
84,3,1,3,0,3,0,.1,1,“OthAuto”,1,77,0
85,.1,1,.1,0,.1,0,.1,1,“ABBA”,0,64,1
85,4,0,4,0,4,0,2,0,“Prosth”,0,64,1
86,5,1,5,0,5,0,1,1,“OthAuto”,0,76,0
86,4,0,4,0,4,0,2,0,“Prosth”,0,76,0
87,30,0,30,0,30,0,27,0,“OthAuto”,1,50,0
88,17,1,19,0,19,0,15,0,“OthAuto”,1,17,0
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89,5,0,5,0,5,0,3,0,“ABBA”,0,60,0
90,25,0,25,0,25,0,23,0,“OthAuto”,1,59,0
91,3,0,3,0,3,0,,,“Prosth”,0,61,0
91,14,1,24,1,24,0,24,1,“Prosth”,0,59,0
92,4,0,4,0,4,0,2,0,“OthAuto”,1,68,0
92,3,1,3,0,3,0,1,1,“Prosth”,1,70,0
92,30,1,30,0,30,0,28,1,“OthAuto”,1,68,0
93,15,0,15,0,15,0,13,0,“ABBA”,0,41,0
93,15,0,15,0,15,0,13,0,“ABBA”,0,25,0
94,17,0,17,0,17,0,12,0,“OthAuto”,1,46,0
95,21,0,21,0,21,0,14,0,“OthAuto”,1,54,0
96,.1,1,.1,0,.1,0,.1,1,“ABBA”,1,43,0
97,12,0,12,0,12,0,,,“OthAuto”,1,50,0
98,12,1,12,0,12,0,0,1,“Prosth”,0,35,0
98,15,0,15,0,15,0,13,0,“ABBA”,0,36,0
99,3,1,,,7,0,4,0,“Prosth”,0,54,0
99,2,1,2,0,2,0,.1,1,“OthAuto”,0,54,0
99,3,1,3,0,3,0,.1,1,“OthAuto”,0,54,0
100,6,0,6,0,6,0,4,0,“OthAuto”,0,68,0
101,5,0,5,0,5,0,,,“OthAuto”,1,59,0
102,1,1,,,22,0,22,0,“Prosth”,1,32,0
103,16,0,16,0,16,0,14,0,“OthAuto”,0,38,0
104,13,0,13,0,13,0,9,0,“ABBA”,1,43,1Appendix, online only. Continued.
105,10,0,10,0,10,0,8,0,“ABBA”,1,30,0
106,10,0,10,0,10,0,,,“OthAuto”,1,67,0
107,9,0,9,0,9,0,7,0,“ABBA”,0,70,0
108,16,0,16,0,16,0,14,0,“ABBA”,1,76,0
109,14,0,14,0,14,0,12,0,“OthAuto”,0,43,0
110,16,0,16,0,16,0,14,0,“OthAuto”,1,63,0
111,5,0,5,0,5,0,,,“OthAuto”,1,57,0
112,4,1,4,0,4,0,3,1,“Prosth”,0,45,0
113,12,0,12,0,12,0,9,0,“OthAuto”,1,56,0
114,10,1,19,1,19,0,15,1,“ABBA”,0,52,0
115,34,0,34,0,34,0,31,0,“OthAuto”,1,48,0
116,5,0,5,0,5,0,,,“OthAuto”,1,66,0
116,2,1,2,0,2,0,.1,1,“OthAuto”,1,66,0
117,6,1,17,0,17,0,13,0,“OthAuto”,0,58,0
118,33,0,33,0,33,0,31,0,“ABBA”,1,60,0
119,6,0,6,0,6,0,3,0,“OthAuto”,1,66,0
120,20,0,20,0,20,0,18,0,“OthAuto”,1,54,0
121,6,0,6,0,6,0,1,0,“ABBA”,1,41,0
122,.1,1,.1,0,.1,0,.1,1,“ABBA”,0,74,1
122,12,0,12,0,12,0,11,0,“Prosth”,0,74,1
